IP Verse

N-(Azaaryl)Cyclolactam-1-Carboxamide Derivative, Preparation Method Therefor, And Use Thereof - EP3632907

The patent EP3632907 was granted to Abbisko Therapeutics on Feb 28, 2024. The application was originally filed on May 22, 2018 under application number EP18805288A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3632907

ABBISKO THERAPEUTICS
Application Number
EP18805288A
Filing Date
May 22, 2018
Status
Granted And Under Opposition
Jan 26, 2024
Grant Date
Feb 28, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DECIPHERA PHARMACEUTICALSNov 13, 2024MARKS & CLERKADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2006067445
INTERNATIONAL-SEARCH-REPORTWO2014145015
INTERNATIONAL-SEARCH-REPORTWO2014145023
INTERNATIONAL-SEARCH-REPORTWO2014145028
OPPOSITIONWO2014145015
OPPOSITIONWO2014145028
OTHERWO2014145028

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Silverman Richard B. ET AL, "The Organic Chemistry of Drug Design and Drug Action", doi:10.1016/B978-0-12-382030-3.00002-7, ISBN 978-0-12-382030-3, (20140101), pages 19 - 122, Elsevier, URL: http://dx.doi.org/10.1016/B978-0-12-382030-3.00002-7, XP055964547
OPPOSITION- D5 - Details of biochemical assay for CSF1R, uKIT, uPDGFRa, FLT3 and KDR-
OPPOSITION- D6 - Biological test evaluation-
OPPOSITION- Kumari Archana, Kaur Maninder, Bahia Malkeet Singh, Silakari Om, "3D-QSAR analysis of anilinoquinoline inhibitors of colony stimulating factor-1 kinase (cFMS): implementation of field-based molecular alignment", Medicinal Chemistry Research,, US , (20131101), vol. 22, no. 11, doi:10.1007/s00044-013-0513-8, ISSN 1054-2523, pages 5167 - 5183, XP093270990
OPPOSITION- Silverman Richard B., Holladay Mark W., "Lead Discovery and Lead Modification", The Organic Chemistry of Drug Design and Drug Action, Elsevier, (20140101), pages 19 - 122, doi:10.1016/B978-0-12-382030-3.00002-7, ISBN 978-0-12-382030-3, XP055964547
OPPOSITION- Zengjun Fang, Yu'ning Song, Peng Zhan, Qingzhu Zhang, Xinyong Liu, "Conformational Restriction: An Effective Tactic in ‘Follow-On’-Based Drug Discovery", Future medicinal chemistry, London : Future Science, UK, UK , (20140501), vol. 6, no. 8, doi:10.4155/fmc.14.50, ISSN 1756-8927, pages 885 - 901, XP009559783
SEARCH- PAOLA CIAPETTI AND BRUNO GIETHLEN ED - CAMILLE GEORGES WERMUTH, Chapter 15 - Molecular Variations Based on Isosteric Replacements, THE PRACTICE OF MEDICINAL CHEMISTRY (THIRD EDITION), ELSEVIER, NL, PAGE(S) 290 - 342, (20080101), ISBN 978-0-12-374194-3, XP009142466 [A] 1-19 * page 296; figure 15.7 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents